Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

Keros Therapeutics (KROS) Preferred Shares Issued (2020)

Keros Therapeutics filings provide 1 years of Preferred Shares Issued readings, the most recent being $56.0 million for Q1 2020.

On a quarterly basis, Preferred Shares Issued changed N/A to $56.0 million in Q1 2020 year-over-year; TTM through Dec 2020 was $56.0 million, a N/A change, with the full-year FY2020 number at $56.0 million, changed N/A from a year prior.
Preferred Shares Issued hit $56.0 million in Q1 2020 for Keros Therapeutics.
In the past five years, Preferred Shares Issued ranged from a high of $56.0 million in Q1 2020 to a low of $56.0 million in Q1 2020.